Allelic variation of the matrix metalloproteinase-9 gene is associated with collagenous colitis

Inflammatory Bowel Diseases

Volumn 17, Issue 11, 2011, Pages 2295-2298

  Madisch, Ahmed ^a   Hellmig, Stephan ^b   Schreiber, Stephan ^c   Bethke, Birgit ^d   Stolte, Manfred ^d   Miehlke, Stephan ^e  

^a Medical Department i   (Germany)

^b Medical Department   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Klinikum Kulmbach   (Germany)

^e Center for Digestive Diseases   (Germany)

Author keywords

collagenous colitis; matrix metalloproteinase

Indexed keywords

GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN;

ADULT; AGED; ALLELISM; ARTICLE; COLLAGENOUS COLITIS; CONTROLLED STUDY; EXON; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; CASE-CONTROL STUDIES; COLITIS, COLLAGENOUS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 80054766162     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21640     Document Type: Article

References (33)

1. Tremaine WJ,. Collagenous colitis and lymphocytic colitis. J Clin Gastroenterol. 2000; 30: 245-249. (Pubitemid 30194629)
2. Madisch A, Morgner A, Stolte M, et al. Investigational treatment options in microscopic colitis. Expert Opin Investig Drugs. 2008; 17: 1829-1837.
3. Pardi DS,. Microscopic colitis-an update. Inflamm Bowel Dis. 2004; 10: 860-870.
4. Madisch A, Heymer P, Voss C, et al. Oral budesonide therapy improves quality of life in patients with collagenous colitis-results of placebo-controlled, multicenter trial. Int J Colorectal Dis. 2005; 20: 312-316. (Pubitemid 40909227)
5. Lindstrom CG,. Collagenous colitis with watery diarrhoea: a new entity? Pathol Eur. 1976; 11: 87-93.
6. Bogomoletz WV,. Collagenous, microscopic and lymphocytic colitis. An evolving concept. Virchows Arch. 1994; 6: 573-579. (Pubitemid 24245326)
7. Bohr J, Olesen M, Tysk C, et al. Collagenous and lymphocytic colitis: a clinical and histopathological review. Can J Gastroenterol. 2000; 14: 943-947. (Pubitemid 32103396)
8. Bohr J, Tysk C, Eriksson S, et al. Collagenous colitis: a retrospective study of clinical presentation and treatment in 163 patients. Gut. 1996; 39: 846-851. (Pubitemid 27049088)
9. Fernández-Bañares F, Esteve M, Espinõs JC, et al. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol. 2007; 102: 324-330. (Pubitemid 46160546)
10. Ung KA, Gillberg L, Kilander A, et al. Role of bile acids and bile acid binding agents in patients with collagenous colitis. Gut. 2000; 46: 170-175. (Pubitemid 30305841)
11. Ung KA, Kilander RA, Willen R, et al. Role of bile acids in lymphocytic colitis. Hepatogastroenterology. 2002; 49: 432-437. (Pubitemid 34606568)
12. van Tilburg AJ, Lam HG, Seldenrijk CA, et al. Familial occurrence of collagenous colitis. A report of two families. J Clin Gastroenterol. 1990; 12: 279-285. (Pubitemid 20207686)
13. Abdo AA, Zetler PJ, Halparin LS,. Familial microscopic colitis. Can J Gastroenterol. 2001; 15: 341-343. (Pubitemid 32600130)
14. Griga T, Tromm A, Schmiegel W, et al. Collagenous colitis: implications for the role of vascular endothelial growth factor in repair mechanisms. Eur J Gastroenterol Hepatol. 2004; 16: 397-402. (Pubitemid 38453418)
15. Taha Y, Raab Y, Larrson A, et al. Vascular endothelial growth factor (VEGF)-a possible mediator of inflammation and mucosal permeability in patients with collagenous colitis. Dig Dis Sci. 2004; 49: 109-130.
16. Hellmig S, Ott S, Rosenstiel P, et al. Genetic variants in matrix metalloproteinase genes are associated with development of gastric ulcer in H. pylori infection. Am J Gastroenterol. 2006; 101: 29-35. (Pubitemid 43381705)
17. Saarialho-Kere UK, Vaalamo M, Puolakkainen P, et al. Enhanced expression of matrilysin, collagenase, and stromelysin-1 in gastrointestinal ulcers. Am J Pathol. 1996; 148: 519-526. (Pubitemid 26056736)
18. Schuppan D, Hahn EG,. MMPs in the gut: inflammation hits the matrix. Gut. 2000; 47: 12-14.
19. Brinckerhoff CE, Matrisian LM,. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol. 2002; 3: 207-214.
20. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000; 47: 63-73. (Pubitemid 30430413)
21. Mott JD, Werb Z,. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol. 2004; 16: 558-564. (Pubitemid 39201241)
22. Madisch A, Hellmig S, Schreiber S, et al. NOD2/CARD15 gene polymorphisms are not associated with collagenous colitis. Int J Colorectal Dis. 2007; 22: 1445-1451.
23. Miehlke S, Heymer P, Bethke B, et al. Budesonide treatment for collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology. 2002; 123: 978-984.
24. Madisch A, Miehlke S, Eichele E, et al. Boswellia serrata extract for the treatment of collagenous colitis: a randomized, double-blind, placebo-controlled, multicenter trial. Int J Colorectal Dis. 2007; 22: 1445-1445.
25. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411: 599-603. (Pubitemid 32531408)
26. Hampe J, Cuthbert A, Croucher PJ, et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet. 2001; 357: 1925-1928. (Pubitemid 32568333)
27. Järnerot G, Tysk C, Bohr J, et al. Collagenous colitis and fecal stream diversion. Gastroenterology. 1995; 109: 449-455.
28. Aigner T, Neureiter D, Muller S, et al. Extracellular matrix composition and gene expression in collagenous colitis. Gastroenterology. 1997; 113: 136-143. (Pubitemid 27281767)
29. Gunther U, Schuppan D, Bauer M, et al. Fibrogenesis and fibrolysis in collagenous colitis. Patterns of procollagen types I and IV, matrix-metalloproteinase-1 and -13, and TIMP-1 gene expression. Am J Pathol. 1999; 155: 493-503. (Pubitemid 29370399)
30. Vaalamo M, Karjalainen-Lindsberg ML, Puolakkainen P, et al. Distinct expression profiles of stromelysin-2 (MMP-10), collagenase-3 (MMP-13), macrophage metalloelastase (MMP-12), and tissue inhibitor of metalloproteinases-3 (TIMP-3) in intestinal ulcerations. Am J Pathol. 1998; 152: 1005-1014. (Pubitemid 28173362)
31. Bailey CJ, Hembry RM, Alexander A, et al. Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B, and collagenase in Crohn's disease and normal intestine. J Clin Pathol. 1994; 47: 113-116. (Pubitemid 24095461)
32. Castaneda FE, Walia B, Vijay-Kumar M, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology. 2005; 129: 1991-2008. (Pubitemid 41772976)
33. Ayata G, Ithamukkala S, Sapp H, et al. Prevalence and significance of inflammatory bowel disease-like morphologic features in collagenous and lymphocytic colitis. Am J Surg Pathol. 2002; 26: 1414-1423. (Pubitemid 35239417)